Е Н Александрова
About
In The Last Decade
Е Н Александрова
173 papers receiving 524 citations
Peers
Comparison fields: 5 of 84
- Rheumatology 374
- Immunology 161
- Hematology 106
- Molecular Biology 90
- Pathology and Forensic Medicine 88
Countries citing papers authored by Е Н Александрова
This map shows the geographic impact of Е Н Александрова's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Е Н Александрова with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Е Н Александрова more than expected).
Fields of papers citing papers by Е Н Александрова
This network shows the impact of papers produced by Е Н Александрова. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Е Н Александрова. The network helps show where Е Н Александрова may publish in the future.
Co-authorship network of co-authors of Е Н Александрова
This figure shows the co-authorship network connecting the top 25 collaborators of Е Н Александрова. A scholar is included among the top collaborators of Е Н Александрова based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Е Н Александрова. Е Н Александрова is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 1 | |
| 4 | 3 | |
| 5 | 1 | |
| 6 | 8 | |
| 7 | 7 | |
| 8 | 2 | |
| 9 | 1 | |
| 10 | Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment | 1 |
| 11 | 1 | |
| 12 | Иммунологические предикторы эффекта анти-В-клеточной терапии при ревматоидном артрите | 1 |
| 13 | Study of the relationship between innovation and export activity of Russian firms | 2 |
| 14 | Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome | 1 |
| 15 | Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: A pilot study | 1 |
| 16 | Recurrences of thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin | 2 |
| 17 | Rheumatic diseases: Current technologies and perspectives of laboratory diagnosis | 0 |
| 18 | Soluble CD40 Ligand in systemic lupus erythematosus: link with atherosclerotic vascular affection | 3 |
| 19 | [Early diagnosis of rheumatoid arthritis in modern clinical practice (results of a follow-up of a Moscow cohort of early arthritis patients participating in the program RADICAL)]. | 3 |
| 20 | Early diagnosis of rheumatoid arthritis in modern clinical practice (results of a follow-up of a Moscow cohort of early arthritis patients participating in the program RADICAL) | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.